Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Farmers Insurance
Queensland Health
Teva
Daiichi Sankyo
Merck
McKesson
Cantor Fitzgerald
Healthtrust

Generated: February 22, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CRISABOROLE

« Back to Dashboard

Clinical Trials for Crisaborole

Trial ID Title Status Sponsor Phase Summary
NCT03233529 Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis Not yet recruiting Pfizer Phase 2 This study is being conducted to characterize the mechanism of action of crisaborole ointment 2%, by evaluation of efficacy and changes in key skin biomarkers in atopic dermatitis (AD) lesions treated with crisaborole ointment 2% over vehicle, in subjects with mild to moderate AD. Two identified AD skin lesions for each subject will be treated for the first 15 days, one with crisaborole ointment 2% and one with vehicle, in a blinded manner, and biopsies for biomarker analysis will be performed on the lesions. Following completion of the blinded treatment period, subjects will start the 28 day open label period during which all AD affected skin lesions will be treated with crisaborole ointment 2% twice daily.
NCT03260595 A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatit Not yet recruiting Pfizer Phase 1 This is a Phase 1 parallel-cohort study of crisaborole ointment 2% to evaluate the skin irritation potential in adult Japanese healthy subjects in Cohort 1, and to evaluate the safety, tolerability and PK in adult Japanese subjects with mild to moderate AD in Cohort 2.
NCT03351114 Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea Not yet recruiting Pfizer Phase 2 This is a pilot study to determine the safety and clinical efficacy of crisaborole 2% ointment in the treatment of morphea.
NCT03351114 Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea Not yet recruiting Duke University Phase 2 This is a pilot study to determine the safety and clinical efficacy of crisaborole 2% ointment in the treatment of morphea.
NCT03356977 A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis Not yet recruiting Pfizer Phase 4 This 4-week study will evaluate the safety, pharmacokinetics (PK), and efficacy of crisaborole ointment 2%, applied twice daily (BID) in subjects who are 3 months to less than 24 months of age with mild-to-moderate AD.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Crisaborole

Condition Name

Condition Name for Crisaborole
Intervention Trials
Atopic Dermatitis 3
Healthy 2
Seborrheic Dermatitis 1
Morphea 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Crisaborole
Intervention Trials
Dermatitis 5
Eczema 4
Dermatitis, Atopic 4
Dermatitis, Seborrheic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Crisaborole

Trials by Country

Trials by Country for Crisaborole
Location Trials
United States 10
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Crisaborole
Location Trials
Kentucky 2
Arkansas 2
Connecticut 1
Virginia 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Crisaborole

Clinical Trial Phase

Clinical Trial Phase for Crisaborole
Clinical Trial Phase Trials
Phase 4 3
Phase 2 2
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Crisaborole
Clinical Trial Phase Trials
Not yet recruiting 5
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Crisaborole

Sponsor Name

Sponsor Name for Crisaborole
Sponsor Trials
Pfizer 6
University of Alabama at Birmingham 1
Duke University 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Crisaborole
Sponsor Trials
Industry 6
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Express Scripts
US Army
Teva
Covington
Johnson and Johnson
Medtronic
Argus Health
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.